Pharmaceutical use of isolarisiresinol

Abstract

Disclosed is the pharmaceutical use of isolarisiresinol in preparing medicament for treating intestinal endotoxemia and lowering mortality caused by multiple-organ prostration induced thereby, The invention also discloses the its use in preparing medicament for treating intestinal endotoxemia caused by serious wounds, burns, war wounds, infection, major operation, heavy shock, radiotheraphy, chemotherapy, or organ transplantation stress condition, or intestinal endotoxemia as the complication of serious hepatitis, cirrhosis, gastrointestinal tract diseases, undernourishment, biliary tract intestinal obstruction, or intestinal endotoxemia induced pyaemia, purulent shock, multiple-organ dysfunction or prostration, and the use in preparing medicament for treating septicemia, acute pneumonia, acute liver prostration, acute DIC, prostration syndrome of serious shocks, and diseases caused by cytomegalovirus, herpesvirus, and influenza virus.

Description

technical field

[0001] The present invention relates to the medicinal use of a compound, in particular to the medicinal use of isolaricine resinol. The patent application of the present invention is a divisional application, the original application number is 031020658, the application date is January 30, 2003, and the title of the invention is a plant extract and compound for treating endotoxemia, its extraction method and application. Background technique

[0002] Endotoxin ET is the lipopolysaccharide (Lopipolysaccharide LPS) component of the cell wall of Gram-negative bacilli, and is a key pathogenic factor that mediates abnormal immune and inflammatory responses in the body. Endotoxemia is caused by the excessive entry of endogenous and exogenous endotoxins into the blood circulation, stimulating the body's immune cells to release a large number of cytokines, disrupting the balance of the body's inflammatory response, causing microcirculation disturbance and severe tiss...

Images